320 Hatch Dr.
14 articles with Notable Labs
Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer
Notable Labs, Inc., a clinical-stage platform therapeutics company, announced the appointment of Kevin Lynch, Ph.D., MBA, as Chief Business Officer.
Notable Presents Clinical Validation Data from Two Phase 2 Trials in Adult and Pediatric Acute Myelogenous Leukemia at the 63rd American Society of Hematology (ASH) Annual Meeting
Notable Labs, Inc., a clinical-stage platform therapeutics company, announced results from two ongoing Phase 2 clinical trials examining the performance of its high-fidelity predictive precision medicines platform in predicting clinical outcomes in acute myelogenous leukemia standard-of-care settings.
Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement
Notable Labs, Inc., a clinical-stage predictive precision therapeutics company and CicloMed LLC, a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of fosciclopirox in patients with refractory acute myelogenous leukemia under the terms of a co-development agreement.
Notable Expands Executive Leadership Team with Appointment of Christopher Whitmore as Chief Financial Officer
Notable Labs, Inc., a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, announced the appointment of Chris Whitmore as Chief Financial Officer.
Clinical Data on the Notable Predictive Precision Medicines Platform Presented at the 63rd ASH Annual Meeting
Notable Labs, Inc., a clinical-stage platform therapeutics company, announced two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology Annual Meeting and Exposition.
Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib
Notable Labs, Inc., a pioneer and developer of predictive precision medicines, has obtained worldwide rights to volasertib from Oncoheroes Biosciences Inc., a Boston-based biotechnology company focused on advancing new therapies for childhood cancer.
Life sciences veteran Thomas Brock is helming a new therapeutic pipeline at Notable Labs, a company that has primarily been known for its oncology-testing services.
There’s plenty of money on the move as venture capital firms and investors look to the future of biotech. Read on for today’s top Series A rounds.
Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, announced their partnership.
Notable , which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Dr. Thomas A. Bock to its board of directors. Bock is a recognized life science leader who built four entrepreneurial organizations that created major impact for both patients and investors, achieving leadership in their fields. He successfully spearheade
Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.
Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies
First peer-reviewed publication highlighting Notable’s platform published today in Blood Advances
It's no secret that artificial intelligence and machine learning play key roles in drug development. This week, multiple companies have advanced their AI programming.
In Personalized Medicine Feasibility Study, Stanford Medical Center, With Partners Notable and Tempus, Able to Make Rapid Personalized Treatment Recommendations for 100 Percent of Blood Cancer Patients
With respect to accuracy, interim clinical data demonstrated both positive and negative predictive value average of 84 percent.